Biocon surges as its arm gets USFDA’`s nod for Bosaya, Aukelso
Biocon is currently trading at Rs. 363.15, up by 8.75 points or 2.47% from its previous closing of Rs. 354.40 on the BSE.
The scrip opened at Rs. 359.00 and has touched a high and low of Rs. 363.45 and Rs. 358.10 respectively. So far 163947 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 405.90 on 18-Jul-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 368.05 and Rs. 353.00 respectively. The current market cap of the company is Rs. 48043.79 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.86% and 16.68% respectively.
Biocon’s subsidiary -- Biocon Biologics (BBL) has received approval from U.S. Food and Drug Administration (USFDA) for Bosaya (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia and Xgeva respectively. In addition, the USFDA granted provisional interchangeability designation for both BOSAYA and AUKELSO.
BOSAYA is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
AUKELSO is approved for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
